General Assembly Meeting 2017

January 16-17 – 2017 Pisa
Venue: Sala Azzurra, Palazzo della Carovana
Scuola Normale Superiore
Piazza dei Cavalieri, 7

DRAFT AGENDA

PRESENTATION OF THE WORK PACKAGES BY WP LEADERS AND RELEVANT PARTICIPANTS

2:00 PM to 3:00 PM

WP1 Understanding the mechanism of NGF system regulation of NP and OA
WP Leader AU
Other participants: LEVI , EBRI, MUW, USAL, KCL, INSERM
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

3:00 PM to 4:00 PM

WP2 Understanding Endocannabinoid signalling in NP
WP leader MUW
Other participants: EBRI ,INSERM
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

4:00 PM to 5:00 PM

WP3 Molecular Mechanism of HSAN IV and HSAN V Neuropathies: “Suffering without Pain”
WP Leader SNS
Other participants: EBRI, KCL, USAL
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

5:00 PM TO 5:30 PM COFFEE BREAK

5:30 PM to 6:30 PM

WP5 Controlling Pain
WP Leader EBRI
Other participants: SNS, AU, LEVI, INSERM, KCL, USAL
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

6:30 PM to 7:30 PM: Overall discussion on the project

9:00 PM SOCIAL DINNER

9:00 AM to 10:00 AM

WP4 New targets for NP and OA: gene expression profiling and epigenetic regulation of NP and OA
WP Leader GEN
Other participants: EBRI, USAL
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

10:00 AM to 11:00 AM

WP6 Safety issues related to antiNGF therapies
WP Leader LEVI
Other participants: SNS, EBRI
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

11:00 AM TO 11:30 PM COFFEE BREAK
11:30 AM to 12:30 AM

WP7 Structure based optimization of lead drug candidates
WP Leader KCL
Other participants: SNS, EBRI
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

12:30 AM to 1:30 PM

WP8 Identification of NP and OA biomarkers for patients stratification

WP Leader USAL
Other participants: MUW, SNS, EBRI, LEVI
Part I: data (Work Progress, Deliverables and Milestones)
Part II: Critical Points and Plan foreseen by the DoW for the end of the project
Discussion

1:30 PM TO 2:30 PM LUNCH BREAK

2:30 PM to 3:30 PM: Overall discussion on the project

END OF MEETING 3:30 PM

DOWNLOAD THE LIST OF HOTELS